Juvenile Myelomonocytic Leukemia (JMML) Ongoing Global Clinical Trials Analysis and Outlook

June 2018 | 116 pages | ID: JA6A9DD428CEN
VPAResearch

Abstracts

Juvenile Myelomonocytic Leukemia (JMML) ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Juvenile Myelomonocytic Leukemia (JMML) disease clinical trials. The research work analyzes the ongoing Juvenile Myelomonocytic Leukemia (JMML) clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Juvenile Myelomonocytic Leukemia (JMML) treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Juvenile Myelomonocytic Leukemia (JMML) clinical trials.

Scope of the Report-

• Ongoing Juvenile Myelomonocytic Leukemia (JMML) clinical trials across regions
• Trial information by Phase and Subjects recruited
• Trial information by status, type, sponsor type
• Drugs used for treatment of Juvenile Myelomonocytic Leukemia (JMML)
• Both observational and interventional trials analyzed
• Leading companies and universities participating in Juvenile Myelomonocytic Leukemia (JMML) clinical trials

Reasons to Buy

• Track competition and design competitive advantages
• Identify right partners to associate with for further research
• Evaluate potential opportunities available in further clinical trials of the disease
• Formulate business development strategies through success rates of clinical trials
• Identify quick markets for recruiting subjects based on trials count by each market

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 KEY FINDINGS, 2018

2.1 Snapshot
2.2 Overview of Juvenile Myelomonocytic Leukemia (JMML) Trials

3 CLINICAL TRIALS TRENDS TO 2022

3.1 Ongoing Juvenile Myelomonocytic Leukemia (JMML) Trials by Phase
3.2 Ongoing Juvenile Myelomonocytic Leukemia (JMML) Trials by Type
3.3 Ongoing Juvenile Myelomonocytic Leukemia (JMML) Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

4.1 Region wise Ongoing Juvenile Myelomonocytic Leukemia (JMML) Trials
4.2 Top 10 Countries conducting Juvenile Myelomonocytic Leukemia (JMML) Trials
4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

5.1 Ongoing Juvenile Myelomonocytic Leukemia (JMML) Trials by Sponsor Type
5.2 Juvenile Myelomonocytic Leukemia (JMML) Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

6.1 Subjects Recruited for Juvenile Myelomonocytic Leukemia (JMML) Trials by year
6.2 Subjects Recruited for Juvenile Myelomonocytic Leukemia (JMML) Trials by Phase
6.3 Subjects Recruited for Juvenile Myelomonocytic Leukemia (JMML) Trials by Trial Type
6.4 Subjects Recruited for Juvenile Myelomonocytic Leukemia (JMML) Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Juvenile Myelomonocytic Leukemia (JMML) Trials- Phase
7.2 Ongoing Juvenile Myelomonocytic Leukemia (JMML) Trials- Phase
7.3 Ongoing Juvenile Myelomonocytic Leukemia (JMML) Trials- Phase
7.4 Ongoing Juvenile Myelomonocytic Leukemia (JMML) Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials by Country
Figure 2: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials by Phase of Development, 2018
Figure 3: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials by Status, 2018
Figure 4: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials by Type, 2018
Figure 5: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials Split by Region, 2000-2018
Figure 6: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials by Type of Economy, 2018
Figure 7: Juvenile Myelomonocytic Leukemia (JMML)- Enrolment by Phase, 2018
Figure 8: Juvenile Myelomonocytic Leukemia (JMML)- Enrolment by Trial Type, 2018
Figure 9: Juvenile Myelomonocytic Leukemia (JMML)- Enrolment by Recruitment Status, 2018
Figure 10: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials by Sponsor Type, 2018
Figure 11: Juvenile Myelomonocytic Leukemia (JMML)- Enrolment by Type of Sponsors
Figure 12: Juvenile Myelomonocytic Leukemia (JMML)- Enrolment by Leading Sponsors

List Of Tables

LIST OF TABLES

Table 1: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials by Sponsor Type, 2018
Table 2: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials by Economy Type, 2018
Table 3: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials by Region, 2018
Table 4: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Juvenile Myelomonocytic Leukemia (JMML)- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Juvenile Myelomonocytic Leukemia (JMML)- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Juvenile Myelomonocytic Leukemia (JMML)- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Juvenile Myelomonocytic Leukemia (JMML)- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Juvenile Myelomonocytic Leukemia (JMML)- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company